A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion
Research output: Contribution to journal › Journal article › Research › peer-review
Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.
| Original language | English |
|---|---|
| Journal | Circulation. Arrhythmia and Electrophysiology |
| Volume | 4 |
| Issue number | 5 |
| Pages (from-to) | 637-43 |
| Number of pages | 7 |
| ISSN | 1941-3149 |
| DOIs | |
| Publication status | Published - 2011 |
ID: 40200182